The roles of mesenchymal stem cells secretome in diabetic wound healing
There has been a fourfold rise in the number of diabetics from 108 million in 1980 to 422 million in 2014 and by 2040 the number will reach to 642 million. Diabetes mellitus drastically influences normal functioning of the affected individual including the natural process of wound healing which is impaired. Therefore, diabetic foot ulcer have become a significant cause of diabetes related amputations, which lead to high medical cost and poor life quality of patients.
Skin wound healing involves distinct but overlapping phases of hemostasis, inflammation, proliferation, and remodeling. A diverse set of cells such as neutrophils, macrophages, and fibroblasts contribute to the process of different phases of skin wound healing. Mechanisms underlying poor healing of diabetic wounds are still unclear, yet the reasons for this dread complication of diabetes mainly involves hypoxia, impaired angiogenesis, damage from reactive oxygen species (ROS), and neuropathy, leads to long-time medical burden and compromised life quality of those patients. Conventional clinical treatment of diabetic wounds often seem ineffective for many patients due to impaired cell function around the wound sites.
To solve these problems, therapies based on mesenchymal stem cells (MSCs) showed great potential for wound healing due to their secretome. It is shown that MSC secretome contains a variety of cytokines, chemokines, and growth factors that enhance wound healing through improvement of epithelial and endothelial cell migration, granular tissue formation, and angiogenesis.
Since fibroblast plays a key role in wound healing, and the advantages of mesenchymal stem cellssecretome in wound healing have been reported we scrutinized the impact of MSC-secretome on diabetics wound healing and skin regeneration. Our findings revealed significant improvements in some healing kinetics of diabetic wound which received MSC-secretome Particularly, MSC-secretome-treated diabetic wounds reached considerably higher percentages of wound closure. Also, the granulation tissue of these wound had less pronounced inflammatory response, better tissue remodeling, and more vascularization compared with non-treated diabetic ones. Based on these findings, it is suggested that MSC-secretome could promote wound repair and skin regeneration, in some major processes, via improvement of cellular behaviors of fbroblasts in the diabetic microenvironment. The beneficial advantages of mesenchymal stem cells-secretome on fibroblast cellular behaviors and wound healing may lead to establish a novel approach as an alternative therapeutic procedure to cure chronic wounds in diabetic conditions.
Mona Saheli 1, Mohammad Bayat 2,3, Rasoul Ganji 2, Farzane Hendudari 2,4, Raziyeh Kheirjou 2, Mohammad Pakzad 5, Baran Najar 2, Abbas Piryaei 2,5,6
1Department of Anatomical Sciences, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, 1985717443 Tehran, Iran
3Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of Radiology, Ayatollah Khansari Hospital, Arak University of Medical Sciences, Arak, Iran
5Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
6Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Human mesenchymal stem cells-conditioned medium improves diabetic wound healing mainly through modulating fibroblast behaviors
Mona Saheli, Mohammad Bayat, Rasoul Ganji, Farzane Hendudari, Raziyeh Kheirjou, Mohammad Pakzad, Baran Najar, Abbas Piryaei
Arch Dermatol Res. 2020 Jul